FDA Regulatory Affairs
A Guide for Prescription Drugs, Medical Devices, and Biologics
Second Edition

Edited by
Douglas J. Pisano
Massachusetts College of Pharmacy and Health Sciences
Boston, Massachusetts, USA

David S. Mantus
Cubist Pharmaceuticals, Inc.
Lexington, Massachusetts, USA

informa
healthcare
New York London
# Contents

*Preface* ............... iii  
*Contributors* ............... vii  

1. **Overview of FDA and Drug Development** .................. 1  
   *Josephine C. Babiarz and Douglas J. Pisano*  

2. **What Is an IND?** .................................... 33  
   *Michael R. Hamrell*  

3. **The New Drug Application** ............................... 69  
   *Charles Monahan and Josephine C. Babiarz*  

4. **Meeting with the FDA** .................................. 109  
   *Alberto Grignolo*  

5. **FDA Medical Device Regulation** .......................... 125  
   *Barry Sall*  

6. **The Development of Orphan Drugs** ........................ 167  
   *Tan T. Nguyen*  

7. **CMC Sections of Regulatory Filings and CMC Regulatory Compliance During Investigational and Postapproval Stages** .................. 187  
   *Prabu Nambiar and Steven R. Koepke*  

8. **Overview of the GxPs for the Regulatory Professional** .... 213  
   *Bob Buckley and Robert Blanks*